INTRODUCTION
Type 2 diabetes mellitus (T2DM) is amongst the most common chronic diseases and is a growing worldwide epidemic [1] . The primary goal of diabetes treatment is to control blood glucose levels [2, 3] . Treatment guidelines recommend metformin as first-line therapy, followed by several options as second-line agents, including sulfonylureas (SU), thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4)
inhibitors, basal insulin, sodium/glucose cotransporter 2 inhibitors, and now also, glucagon-like peptide-1 (GLP-1) receptor agonists [2] [3] [4] . In Germany and the United Kingdom (UK), there are currently six GLP-1 receptor agonists available, twice-daily (BID) exenatide, once-daily (OD) liraglutide, OD lixisenatide, once-weekly exenatide, once-weekly albiglutide and once-weekly dulaglutide which have all been shown to be both effective and safe options for T2DM treatment after metformin failure [5] [6] [7] .
However, despite the number and variety of available T2DM treatment options, it is known from several real-world studies that reaching target glucose levels remains a challenge for many patients [8] [9] [10] . One of the reasons for this may be non-persistence (NPdiscontinuation of a prescribed therapy), and/ or non-adherence (NA) (continued use of therapy, but not as prescribed). Several studies have found a high level of both NP and NA with regards to anti-diabetic therapy [11] [12] [13] [14] [15] [16] and confirmed worse diabetes-related outcomes associated with NP/NA [17] [18] [19] [20] . Much less is known about the level of persistence/adherence to therapy with GLP-1 receptor agonists. Three previous US analyses reported 12-month medication possession ratios (MPRs) of 68% for BID GLP-1 [21] , 69.7% for OD GLP-1 and 64.4% for BID GLP-1 [22] , or 78.3% for once-weekly GLP-1, compared to 50.0% for BID GLP-1 and 68.3-76.1% for OD GLP-1 [23] , the only known European-based study reported a 12-month therapy discontinuation rate of 32.2% for BID therapy with GLP-1 receptor agonists only [24] . Consequently, there is limited real-world data from European T2DM patients about the persistence and adherence to therapy with GLP-1 receptor agonists.
Therefore, our aim was to use two large European datasets, to (1) assess the level of persistence and adherence to therapy with GLP-1 receptor agonists in T2DM patients in UK and Germany, and compare OD with BID therapy and (2) to identify any factors that may explain early discontinuation of therapy with GLP-1 receptor agonists in the first year of therapy as well as to assess outcomes possibly associated with early discontinuation of therapy.
METHODS
Our study had access to two large retrospective datasets: a German claims dataset provided by one large sickness fund (AOK PLUS; 2.7 million insured; http://www.aokplus.de) and the UK
General Practitioner (GP)-based Clinical Practice
Research Datalink (CPRD) database (longitudinal data covering about 4.4 million patients treated by about 500 GPs; http://www.cprd.com; accessed Jan 2015). As far as data available in the two datasets allowed, we used the same methodology for each of the database analyses.
T2DM Samples
This was a retrospective non-interventional cohort analysis based on anonymized data for the calendar years 2010-2012 (separate analyses; no linking of country data). All T2DM patients [at least one outpatient T2DM diagnosis (ICD E11.-or CPRD read codes which are available from the authors upon request) and/or at least one inpatient T2DM diagnosis before index date] who were enrolled continuously in the databases from 01/01/ 2010 until the end of the observational period were included in the analysis; death during the observational period was the only exception to the continuous enrolment requirement. We excluded exenatide in its once-weekly formulation, as it was introduced late in the study period and rarely used. In addition, we did not observe therapy with lixisenatide, albiglutide, and dulaglutide because these agents were approved after end of 2012.
Analysis was done based on treatment-naïve patients only, defined as no prescription of medication of interest in the 6 months before first observed GLP-1 prescription. However, anti-diabetic medication other than the medication of interest was possible. (Fig. 1) .
Assessment of Treatment Persistence
Our analysis was based on the days' supply of the observed prescriptions. To enable comparability between databases, and because of incomplete data with regards to prescribed days of supply, we assumed that the prescribed daily dosage was equal to the WHO defined daily dosage per medication [25] .
NP was defined as a treatment gap of more than 90 days (sensitivity analysis: 180 days). We reported percentage of patients that could be classified as non-persistent at 3, 6, and 12 months after index date. In the German analysis, hospitalizations periods were taken out from observed days because drug's supply was assumed to be provided by hospitals during these days. In contrast, in the UK analysis, information about hospitalization periods was not available for all patients. Furthermore, both in the UK and German analyses, stockpiling was included by assuming that, in case there were overlapping medications, the previous supply was taken fully before the new supply was initiated.
Assessment of Treatment Adherence
Treatment adherence was analyzed in two ways. First, for the overall sample which included those patients who may have discontinued therapy during our preset observation period and those continuing their therapy, we analyzed the overall MPR, defined as number of days' supply received during the whole observational period of 12 months after index date, divided by the number of days in the evaluation period:
In our second NA analysis, we explored adherence only for the period in which a patient continued therapy (no treatment gap [90 days; Fig. 1 
):
Adherence was reported in three ways, first as mean MPR, second as percentage of patients with a MPR\80% and third, in a sensitivity analysis, as percentage of patients with a MPR\70/90%. In the second analysis, we determined in a multivariable logistic regression analysis whether 6-month NP with therapy with GLP-1 receptor agonists (gap [90 days) was associated with a higher probability of experiencing an acute hospitalization with T2DM as main diagnosis (ICD 10 E11.-/E16.0/E16.1/E16.2) in the second 6 months of the observational period. Please note that in this analysis all patients available in the German dataset were included, whereas only a subsample of CPRD T2DM patients for whom hospitalization data were available (Hospital Episode Statistics) were included in the UK analysis.
In the third analysis, we only included T2DM patients which started a therapy with GLP-1 receptor agonists and had at least three HbA1c values documented: at baseline (last value measured before index date), 6-9 months after index date, and 12-18 months after index date.
If more than one value in these periods was available, we used the mean value. Change of HbA1c was compared between patients having continued their therapy with GLP-1 receptor agonists after 6 months versus those having discontinued their therapy at this time.
Statistical Analysis
Discontinuation rates in patient subgroups (GLP-1:
OD/BID) were depicted using Kaplan-Meier curves, significance of differences between discontinuation rates was tested using log-rank tests. To assess any factors predicting discontinuation of therapy with GLP-1 receptor agonists and insulin initiation, we did multivariable Cox regression analyses; for assessment of factors associated with T2DM-hospitalization we did a multivariable logistic regression analysis. The models were estimated based on a backward elimination methodology. All factors not reaching a p value \0.1 were excluded in a stepwise procedure (except age, gender and CCI, which remained in the models as fixed independent variables even if they did not reach statistical significance). Finally, factors reaching a p \0.05 were interpreted as statistically significant. All reported p values were two-sided, and 95% confidence intervals (CIs) were calculated for hazard ratios (HRs)/odds ratios (ORs). Patients with missing data were excluded from the dataset. 
Compliance with Ethics Guidelines
Due to the non-interventional, retrospective nature of the present study and the analysis of an anonymized dataset, no ethical review of this study was necessary. However, the study was evaluated by a scientific steering committee to which all the authors belonged as well as by internal scientific committees belonging to the data owners, the AOK PLUS and CPRD (CPRD Protocol Approval Number: 14_022).
This article does not contain any new studies with human or animal subjects performed by any of the authors.
RESULTS

T2DM Samples
In the UK sample, 1905 T2DM patients started a treatment with GLP-1 receptor agonists during the observation period (mean age: 55.5 years, 47.2% female). In the German sample, 1627 T2DM patients started a treatment with GLP-1 receptor agonists (mean age: 56.6 years, 51.4% female). Out of the total samples, subsets including 1744 UK and 1349 German patients were determined eligible for the adherence analysis. The remaining patients (UK: 8.5%; Germany: 17.1%) discontinued their therapy after only a single prescription.
Main patient characteristics are shown in Table 1 . (BID) in Germany (p\0.010). Table 2 summarizes the results of persistence analysis 
Assessment of Predictors of Discontinuation of Therapy with GLP-1 Receptor Agonists
To be able to assess the influence of the specific treatment regimen with GLP-1 receptor agonists (OD versus BID), only patients who did not switch between BID and OD were included in this analysis (UK: 1628 patients; German: 1475 patients). In German patients, results for age and gender were similar to UK, however, a higher CCI was associated with a higher probability of early GLP-1 NP (HR = 1.051; 95% CI 1.00-1.10). As in the UK, a BID treatment was associated with a higher probability to discontinue a treatment with GLP-1 receptor agonists earlier than an OD treatment (HR = 1.314; 95% CI 1.08-1.60).
Assessment of NP-Related Outcomes
We identified 1398 (73.4%) UK and 1107 (68.0%) German insulin-naïve patients having started a therapy with GLP-1 receptor agonists during our inclusion period. In multivariable Cox regression analyses using time until insulin initiation as dependent variable, among other variables (number of additionally received anti-diabetic agents, visit to diabetologists, retinopathy, neuropathy, diuretics use, female gender), NP to treatment with GLP-1 receptor One of the main advantages of this study is use of two different databases from two European countries, but using the same methodology to calculate treatment persistence/adherence in the analyses. GLP-1 receptor agonists, which may be due to the common gastrointestinal adverse events of these drugs [28] .
A specific characteristic of our study is that it differentiated between treatment adherence and treatment persistence. We think that persistence and adherence to treatment are different real-world phenomena which may be caused by different factors and which may lead to different conclusions. However, in most of the publications known to the authors of this study, adherence and persistence are analyzed jointly so that reported percentage of NA [29] or level of physical activity [30] were not available.
In our analysis of HbA1c progression over time and T2DM-related hospitalizations, we could not include all patients because of data We concluded that OD treatment is associated with a higher persistence than BID treatment with GLP-1 receptor agonists.
However, since exenatide is known to evoke adverse gastrointestinal symptoms more frequently than liraglutide, these persistence differences could also be due to the medicine instead of the intake frequency.
Finally, due to our large sample size, some independent variables may have exerted a statistical influence but, due to low hazards/ odds ratios, not in a clinically meaningful way.
CONCLUSIONS AND IMPLICATIONS FOR PRACTICE
NP to treatment with GLP-1 receptor agonists in both UK and Germany seems to be comparable. Persistence to OD treatment with GLP-1 receptor agonists is higher than to BID treatment with GLP-1 receptor agonists across the UK and 
